IM96 CAR-T therapy for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new treatment called IM96 CAR-T cell therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to standard treatments. The therapy uses your own immune cells, modified in a lab to target a specific marker on your cancer cells, to help fight the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- Your cancer must be advanced stomach or gastroesophageal junction cancer that has spread or can't be removed with surgery.
- You must have already tried standard treatments and they didn't work or caused side effects you couldn't tolerate.
- Your tumor must test positive for a protein called GUCY2C (this is checked with a biopsy).
- You must be in good overall health (ECOG score 0-1) and have adequate organ function, as shown by blood tests and heart tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called IM96 CAR-T, which targets a protein (GUCY2C) found on tumor cells. It is for people with advanced colorectal or stomach cancer that has not responded to standard treatments.
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
This trial tests a new type of cell therapy (CT041) given after surgery and chemotherapy to prevent stomach cancer from coming back. It is for people whose tumors have a specific protein (CLDN18.2) and who have already had standard treatment.
This trial tests a new cell therapy (CT041) for people with advanced stomach or gastroesophageal junction cancer that has a specific marker called CLDN18.2. It is given after initial chemotherapy to try to keep the cancer from growing.
This trial tests a new therapy called CT0494BCP for advanced stomach cancer (including cancers at the junction between the esophagus and stomach) that hasn't responded to at least two prior treatments. The therapy is designed to target a specific protein called CLDN18.2 found on your cancer cells, combined with immune-boosting treatment.
This trial tests a new type of immune cell therapy called KD-496, which is a CAR T-cell designed to attack tumors that have NKG2DL or CLDN18.2 markers. It may be an option for people with advanced solid tumors (commonly stomach or pancreatic cancer) who have tried at least two prior treatments.
Hear when a new Adenocarcinoma of Esophagogastric Junction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.